Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality -7% Improvement Relative Risk ICU admission 57% ARDS 28% Hospitalization time 31% no CI Hospitalization time (b) 73% c19vitamind.com Torres et al. Vitamin D for COVID-19 RCT LATE TREATMENT Favors high dose Favors low dose
Torres, 85 patient vitamin D late treatment RCT: 28% lower ARDS [p=0.74] and 31% shorter hospitalization https://c19p.org/torres
copied to clipboard
Changes in the immune response against SARS-CoV-2 in individuals with severe COVID-19 treated with high dose of vitamin D
Torres et al., Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.112965
14 Apr 2022    Source   PDF   Share   Tweet
RCT comparing 41 patients treated with 10,000IU/day cholecalciferol and 44 treated with 2,000IU/day in Spain, showing significantly shorter hospitalization for ARDS patients with the higher dose. There was also an increase of anti-inflammatory cytokine IL-10 and higher levels of CD4+ T cells. Cytotoxic response against pseudotyped SARS-CoV-2 infected cells was over 4-fold higher in patients receiving the higher dose.
risk of death, 7.3% higher, RR 1.07, p = 1.00, treatment 1 of 41 (2.4%), control 1 of 44 (2.3%).
risk of ICU admission, 57.1% lower, RR 0.43, p = 0.44, treatment 2 of 41 (4.9%), control 5 of 44 (11.4%), NNT 15.
risk of ARDS, 28.5% lower, RR 0.72, p = 0.74, treatment 4 of 41 (9.8%), control 6 of 44 (13.6%), NNT 26.
hospitalization time, 31.2% lower, relative time 0.69, treatment 41, control 44.
hospitalization time, 72.6% lower, relative time 0.27, p = 0.04, ARDS patients.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Torres et al., 14 Apr 2022, Single Blind Randomized Controlled Trial, Spain, peer-reviewed, median age 65.0, 51 authors, study period June 2020 - March 2021, average treatment delay 7.0 days, dosage 10,000IU days 1-14.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit